We are truly humbled by Andrew's courage to share how we provided him a more accurate CLL diagnosis. This led to a crucial shift from a 'wait and see' approach to a targeted therapy plan from his clinical care team. Andrew's journey perfectly reflects our mission to eradicate cancer misdiagnosis. Thank you, Andrew, for sharing your inspiring story with us. #CLL #bloodcancer #moleculardiagnostics #omnia
Precipio, Inc.
医院和医疗保健
New Haven，CT 2,465 位关注者
Precipio’s vision is to battle the problem of cancer misdiagnosis by creating innovative diagnostic products.
关于我们
Since its inception in 2011, Precipio’s (NASDAQ: PRPO) vision is to battle the problem of cancer misdiagnosis, by developing innovative technologies that improve diagnostic accuracy and laboratory workflow, delivering better results to patients and their physicians. In addition to robust R&D and commercial departments developing and bringing to market its proprietary products, Precipio also operates a clinical laboratory that serves as a testing ground for company products from its development phase to full utilization within the clinical setting. Precipio’s Products Division develops, produces, and sells proprietary diagnostic products to laboratories. Precipio also has a Clinical Diagnostics Division which operates the company’s CLIA/CAP laboratory, servicing oncologist practices and hospitals to provide comprehensive diagnostic services, while utilizing the same technologies developed by the Products Division.
- 网站
-
https://www.precipiodx.com/
Precipio, Inc.的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 51-200 人
- 总部
- New Haven，CT
- 类型
- 上市公司
- 创立
- 2011
地点
-
主要
获取路线
4 Science Park
3rd Floor
US，CT，New Haven，06511
Precipio, Inc.员工
动态
-
Join us!
Come join our extraordinary team and help us eradicate cancer misdiagnosis! https://lnkd.in/e_eS86vD #moleculardiagnostics #pathology #oncology
-
-
Come join our extraordinary team and help us eradicate cancer misdiagnosis! https://lnkd.in/e_eS86vD #moleculardiagnostics #pathology #oncology
-
-
Precipio is here at #HEMO2024 in S?o Paulo. If you're here, connect with Ilan Danieli and Daiane Novaes to learn more about our molecular technologies. #moleculardiagnostics #Bloodhound #HemeScreen
-
-
Precipio is here at #HEMO2024 in S?o Paulo. If you're here, connect with Ilan Danieli and Daiane Novaes to learn more about our molecular technologies. #moleculardiagnostics #Bloodhound #HemeScreen
-
-
Precipio Expands Bloodhound? MPN Panel by Adding CALR Mutation Subtyping https://lnkd.in/eEvjEfQt #moleculardiagnostics #MPN #CALR
-
-
Amazing work done by our team. making a difference to patient care.
The Panel Approach to #MPN testing proves crucial once again for accuracy in diagnosis, enabling better patient care. Check out our latest Precipio Spotlight where the Bloodhound MPN Panel detected a JAK2 Exon 13 mutation missed by other test methods. #moleculardiagnostics #hematology https://lnkd.in/dknYBbCW
-
-
The Panel Approach to #MPN testing proves crucial once again for accuracy in diagnosis, enabling better patient care. Check out our latest Precipio Spotlight where the Bloodhound MPN Panel detected a JAK2 Exon 13 mutation missed by other test methods. #moleculardiagnostics #hematology https://lnkd.in/dknYBbCW
-
-
Evaluating the ABL1 gene’s mutation status is a crucial element in monitoring #CML patients. ABL1 mutations can be an earlier indicator of emerging therapy resistance and can better inform clinicians of how to adjust patient therapies. Check out our latest Precipio Spotlight where our clinical lab provided this crucial information to our oncology partner, enabling them to better monitor and care for their patient.?? https://lnkd.in/erJpHXsK #moleculardiagnostics
-
-
Precipio Spotlight: JAK2 Exon 13 mutation co-expressed with CALR mutation in a patient with unspecified thrombocytosis. Detected by Precipio’s clinical hematopathology lab using proprietary molecular technology. https://lnkd.in/eiRksW7P #moleculardiagnostics #MPN
-